Latest Revenue Generation News

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

GWR Group Limited reported $2.53 million in royalties from the Wiluna Iron Ore Project through February 2025 and continues exploration at its Prospect Ridge Magnesium Project with pending assay results. The company holds strong cash reserves and is actively pursuing a major Western Australian acquisition.

NuEnergy Gas Limited has initiated drilling site preparation at its Tanjung Enim PSC, progressing towards early gas sales, while securing key commercial agreements and maintaining a strong cash position.

Resonance Health reports record $14.9M cash receipts over 12 months and completes cost-cutting measures while advancing two major pharma clinical trials on schedule.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Brightstar Resources reported robust March quarter results, highlighted by Second Fortune’s transition to full production and the commencement of Fish mine development, underpinning a clear growth trajectory.

Mt Malcolm Mines NL has reached a significant production milestone within 3.5 years of its ASX listing, generating initial revenue from gold sales while expanding its exploration footprint across multiple prospects in Western Australia's Leonora region.

Humm Group Limited has reported a remarkable 119% increase in cash profit after tax for the half-year ended December 31, 2024, alongside improved capital efficiency and reduced operating expenses. The company declared a fully franked interim dividend, underscoring its strengthened financial position.

Health and Plant Protein Group Limited has dramatically reduced its half-year net loss to $43,000 following the divestment of its macadamia division, though uncertainty lingers over a significant IRS receivable in the US.

Health and Plant Protein Group Limited reported a significantly reduced net loss of $43,000 for the half-year ended December 31, 2024, compared to a $748,000 loss in the prior period, despite no operational revenue following the sale of its macadamia division.

Mighty Kingdom has completed a strategic review, trimming $2.5 million in annual costs without disrupting current contracts and positioning itself for new revenue growth.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.